Immunotherapy and oncology at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

44 organizations at Festival of Biologics 2026 present work in immunotherapy & oncology: 18 drug developers, 14 academic, government and non-profit bodies and 12 suppliers and service providers. Between them they bring 100 presentations to the program. Most represented: Novartis (29 on the program), ETH Zurich (5 on the program), Ichnos Glenmark Innovation (4 on the program). 31 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–4 of 44 organizations

Organization	Festival of Biologics 2026 Attendance
Novartis Basel, Switzerland
novartis.com/about/manufacturing/contract-manufacturing Large pharmaGold sponsor Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish.	Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair's Remarks Clinical Trials Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Antibody Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Immunotherapy Keynotes Talk Tue Oct 13 11:30 Cell Line Development: Powering the Biotherapeutics Pipeline, Accelerating Patient Impact Bioprocessing Keynotes Panel Tue Oct 13 12:20 PANEL DISCUSSION: The Next Frontier: Delivering Next-Gen Science for Patients with High Unmet Need Immunotherapy Keynotes · with Memorial Sloan Kettering Cancer Center, STAb Therapeutics, Transgene +1 more Chair Tue Oct 13 14:05 Chair's Remarks Clinical Development & Operations Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 AI for Immunogenicity Prediction of Biologics AI & Computational Approaches Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. with CSEM, HINA Bioventures, Corning Life Sciences Talk Tue Oct 13 15:30 Antibody x Conjugates: ADCs, AOCs and AxCs mAbs Chair Tue Oct 13 16:45 Chair's Remarks Protein Engineering Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. with UCB, FairJourney Biologics, JJP Biologics Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair's Remarks Gene Therapy Chair Wed Oct 14 11:25 Chair's Remarks Downstream Processing Talk Wed Oct 14 11:30 The Good, the Bad and the Aggregated (Solving Protein Purification Mysteries)? Downstream Processing Talk Wed Oct 14 12:10 Introducing PAT into control strategies CMC & Developability Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Title TBA AI & Computational Approaches Chair Wed Oct 14 14:05 Chair's Remarks AI & Computational Approaches Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair's Remarks Disease Areas: Neurodegenerative & CNS Chair Wed Oct 14 16:45 Chair's Remarks Regulated Bioanalysis Talk Wed Oct 14 16:50 The pivotal role of regulated bioanalysis in biotherapeutics development and approval Regulated Bioanalysis Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Scaling the Future of Cell & Gene Therapies: From Scientific Innovation to Sustainable Platforms Manufacturing Chair Thu Oct 15 11:15 Chair's Remarks Fill/Finish Chair Thu Oct 15 11:15 Chair's Remarks Immunogenicity
ETH Zurich Zurich, Switzerland
	Talk Tue Oct 13 17:50 Title TBA Cell Therapy Chair Wed Oct 14 14:05 Chair's Remarks CMC & Developability Talk Wed Oct 14 15:10 High-Throughput Mechanical Phenotyping of Protein–Protein Interactions A faster way to measure how much pulling force protein pairs can withstand, which can differ from how tightly they bind. Talk Thu Oct 15 12:20 Allogeneic T cells synergising with bispecific antibodies achieve superior Antitumor responses Donor T cells engineered to be activated by two-target antibodies without attacking the patient, tested for stronger anti-tumour responses. Talk Thu Oct 15 12:40 Title TBA Proteomics & Mass Spectrometry
IG Ichnos Glenmark Innovation New York, NY
	Talk Tue Oct 13 14:50 BEAT®: A Platform to Advance Developable Multispecific Therapeutic Antibodies to the Clinic A platform for building antibodies that grip several targets at once, using a shared light chain and pairing ideas borrowed from T-cell receptors. Chair Wed Oct 14 09:00 Chair's Opening Remarks Keynotes Chair Wed Oct 14 14:05 Chair's Remarks Antibodies for Immunotherapy Talk Wed Oct 14 15:30 BEAT®: A Platform To Advance Developable Multispecific Therapeutic Antibodies To The Clinic Bispecifics & Multispecifics Talk Thu Oct 15 11:40 Analytical approaches for developing clinic ready multispecifics antibodies Antibodies for Immunotherapy
P Philochem Otelfingen, Switzerland
Biotech Philogen's Swiss research subsidiary, developing antibody-cytokine fusions and small-molecule ligands for cancer therapy.	Talk Wed Oct 14 15:10 Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results Antibodies for Immunotherapy Talk Wed Oct 14 17:50 Advancing stable cell line development for production of therapeutic antibodies Comparing random gene insertion with placing genes at chosen spots in the genome to get steadier antibody production from cell lines. Talk Thu Oct 15 09:20 Title TBA Targeting the Tumor Microenvironment Talk Thu Oct 15 11:20 Charge Variants characterization of a noncovalent dimeric fusion protein How to measure the different charged forms of a fusion protein whose two halves are not chemically bonded, unlike a standard antibody.